Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Amir Anthony Jazaeri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4335-4151; OpenAlex author ID A5000158770. Sources: ClinicalTrials.gov.

Their work

Papers
1 (first author 0, last author 1)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2018: 1 trial · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 trial · 2024: 1 paper

Papers 1

  1. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Last author DOI 10.1136/jitc-2023-006822↗

Trials 2

  1. Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, … Principal investigator NCT05922930↗
  2. Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Ade… Principal investigator NCT03610490↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael James Overman · 1 shared paper, 2024 · strength 0.16
  2. Milind M. Javle · 1 shared paper, 2024 · strength 0.16
  3. Chantale Bernatchez · 1 shared paper, 2024 · strength 0.16
  4. Donastas Sakellariou-Thompson · 1 shared paper, 2024 · strength 0.16
  5. Rodabe Navroze Amaria · 1 shared paper, 2024 · strength 0.16
  6. Robert A. Wolff · 1 shared paper, 2024 · strength 0.16
  7. Patrick Hwu · 1 shared paper, 2024 · strength 0.16
  8. Scott Kopetz · 1 shared paper, 2024 · strength 0.16
  9. Ying Yuan · 1 shared paper, 2024 · strength 0.16
  10. Shubham Pant · 1 shared paper, 2024 · strength 0.16
  11. Ching-Wei David Tzeng · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.